Background-We report relationships between cardiovascular disease risk factors and myocardial structure, function, and scar in patients with type 1 diabetes mellitus in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Methods and Results-Cardiac magnetic resonance was obtained in 1017 patients with type 1 diabetes mellitus.
T ype 1 diabetes mellitus is associated with an increased risk of cardiovascular disease (CVD) and a high mortality from premature coronary artery disease. 1, 2 Major predictors of CVD for patients with type 1 diabetes mellitus in the Pittsburgh Epidemiology and Diabetes Complications (EDC) Study 3 
and EURODIAB Insulin Dependent Diabetes Mellitus
Complications study 4 included duration of diabetes mellitus, hypertension, elevated lipids, smoking, inflammatory markers, and renal disease. The role of glycemic control on the risk of CVD has been disputed, 3, [5] [6] [7] [8] although long-term studies of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) study cohort have shown an association of hemoglobin A 1c (HbA 1c ) levels with several measures of atherosclerosis and with CVD events. 9 -11 
Clinical Perspective on p 1746
In addition to symptomatic CVD events, patients with type 1 diabetes mellitus may have a propensity for asymptomatic myocardial infarction associated with diabetic autonomic neuropathy. 12 Myocardial dysfunction and nonatherosclerotic myocardial damage, perhaps from microvascular disease, may also occur in patients with type 1 diabetes mellitus. 13 Diabetic cardiomyopathy is associated with left ventricular (LV) hypertrophy, and myocardial dysfunction may result directly from diabetes mellitus in the absence of concomitant atherosclerosis and hypertension. 13 Cardiac magnetic resonance (CMR) imaging is the current reference standard for the assessment of cardiac structure, function, and myocardial scar (dense myocardial fibrosis). 14, 15 The EDIC study is the first large-scale cohort to use CMR to evaluate patients with type 1 diabetes mellitus. The aim of this report is to study the relationships of CVD risk factors and HbA 1c levels with myocardial structure, function, and scar in patients with type 1 diabetes mellitus.
Methods

Study Sample
The DCCT and the EDIC study have been described previously in detail. 16, 17 In brief, between 1983 and 1989, 1441 patients (age, 13-39 years) with type 1 diabetes mellitus were recruited to compare the effects of intensive insulin therapy with conventional therapy. At the baseline visit (1983) (1984) (1985) (1986) (1987) (1988) (1989) , all patients were free of a history of clinical CVD, hypertension, and hypercholesterolemia. DCCT participants were recruited into a primary prevention cohort (1-5 years of diabetes mellitus duration and no retinopathy or microalbuminuria at baseline) or into a secondary intervention cohort (1-15 years of duration, minimal to moderate retinopathy, and no more than 200 mg albuminuria per 24 hours at baseline).
The EDIC study began in 1994 and is an ongoing, prospective, observational follow-up of the DCCT cohort. A total of 1301 participants (94% of the surviving DCCT cohort) were active in EDIC during years 14 to 16 at the time of CMR (Figure 1 ). The study was approved by the institutional review boards of all participating centers, and all subjects gave written informed consent.
Study Procedures
During DCCT, participants underwent an annual medical history and physical examination, ECG, and laboratory testing for fasting lipid levels, serum creatinine, albumin excretion, and other risk factors for CVD. 16 Glycohemoglobin values (HbA 1c ) were measured (in percent of total hemoglobin) quarterly during DCCT and annually during EDIC. 18 During the EDIC follow-up study, lipid profile and urinary albumin excretion rate were measured in alternate years. 17 Weighted mean laboratory values over the study duration were computed with weights proportional to the time interval between values owing to the differences in the intervals between visits during DCCT and EDIC.
Hypertension was defined as blood pressure Ն140/90 mm Hg or use of antihypertensive medications. 17 Hypercholesterolemia was defined as low-density lipoprotein levels Ն130 mg/dL or use of lipid-lowering medication. Alcohol use was self-reported and defined as consumption of an average of at least 1 alcoholic beverage (12 oz beer, 4 oz wine, or 1.5 oz hard liquor) per week in the past year. ECGs were obtained at baseline, at every 2 years during DCCT, at closeout of DCCT, and annually during EDIC; they were centrally read and classified with the revised Minnesota code. 19 -21 
Assessment of Clinical Myocardial Infarction Events and Other Diabetic Complications
All complications were cumulative from the beginning of DCCT to the present study except for neuropathy. CVD included clinical myocardial infarction (MI; nonfatal) or ECG-diagnosed silent MI. Medical records of participants, including ECG findings and cardiac enzyme levels, were submitted for adjudication to a committee masked to treatment group assignment, HbA 1c , and glucose levels. Clinical MI events classified as definite are included in these analyses. Silent MIs were identified on the basis of serial changes in Minnesota codes among all available ECGs during DCCT/EDIC as reported previously. 10 Retinopathy was defined as any proliferative diabetic retinopathy or worse. Nephropathy included sustained microalbuminuria, defined as urinary albumin excretion rate Ͼ30 mg/24 h at any 2 consecutive visits or end-stage renal disease, and macroalbuminuria, defined as albumin excretion rate Ͼ300 mg/24 h at any visit or end-stage renal disease. Neuropathy included cardiac 
CMR Imaging
CMR was performed with a uniform protocol at 27 centers between July 2007 and April 2009 with 1.5-T magnets, except for 1 center that had a 3-T magnet (Espree or Avanto, Siemens Medical Systems, Erlangen, Germany; Intera, Philips Medical Systems, Best, the Netherlands; Signa, GE Medical Systems, Waukesha, WI). Study subjects who agreed to participate and who had an estimated glomerular filtration rate Ն60 mL⅐min Ϫ1 ⅐1.73 m Ϫ2 , 22 no history of dialysis or renal transplantation, or no known allergy to gadolinium also underwent gadolinium-enhanced CMR with a 0.15-to 0.20mmol/kg dose of gadolinium-based contrast.
CMR studies were centrally evaluated by readers blinded to all other study data. LV mass, volumes, and functional parameters were determined with QMASS software (version 6, Medis, Leiden, the Netherlands). A detailed explanation of CMR sequences and image analyses are presented in the Methods section in the online-only Data Supplement.
Myocardial scar was defined as focal enhancement either in 2 adjacent short-axis images or in 1 short-axis image and a long-axis image at a corresponding location. Myocardial scars were classified as either ischemic (involving the subendocardium in a coronary artery distribution) or nonischemic (predominantly midwall or subepicardial location without subendocardial involvement in a noncoronary distribution). For quantitative analysis, myocardial scar areas were traced manually.
Reread of 100 CMR scans revealed an intraclass correlation range from 0.917 to 0.978 and the relative technical error of measurement from 3% to 5% ( Table I in 
Statistical Analysis
Clinical characteristics of DCCT/EDIC participants, measured immediately before or at the time of CMR scan, are reported as meanϮSD or percentage. Groups of subjects were compared by use of the Wilcoxon rank-sum tests for quantitative variables and 2 tests for categorical variables. Differences between groups in rare outcomes were evaluated by a 2-sided Fisher exact test. The reliability of cardiac parameters was evaluated by intraclass correlation and relative technical error measurement. 23 The association of CVD risk factors with LV structure and function was evaluated by use of multivariate linear regression models with machine type (Siemens versus Philips versus GE), age, sex, height, weight, current smoking, current alcohol use, mean systolic blood pressure (SBP), high-density lipoprotein, low-density lipoprotein, and HbA 1c , and macroalbuminuria. Mean SBP was retained in the multivariate regression analyses because it had a stronger association than diastolic blood pressure. Additional analyses used the medication-adjusted mean SBP in which a value of 10 mm Hg was added to every SBP value obtained while a subject was taking antihypertensive medications. The Hochberg multiple testing approach was used to adjust the P values for the covariate effects in each multivariate regression model. 23a The adjusted differences in the risks of myocardial scar and their association with CVD risk factors and LV measures were evaluated with logistic regression models adjusted for age and sex, as appropriate, with 95% confidence intervals (CIs). All analyses were performed with SAS software (version 8.2; SAS Institute, Cary, NC). P values Ͻ0.05 were considered statistically significant.
Results
Study Population
Of the 1301 DCCT/EDIC participants who were active during EDIC years 14 to 16, 1240 participants were screened for CMR; 1017 participants had diagnostic CMR and were included in the analysis (Figure 1 ). Of these, 755 (74%) were also examined with gadolinium-delayed enhancement CMR.
Of 262 who did not receive gadolinium CMR, the majority (173, 66%) were excluded because of moderate or worse renal dysfunction, renal transplantation, or dialysis ( Figure 1 ). The mean age of included participants was 49 years; 48% of them were female; and their mean duration of diabetes mellitus was 28 years. The cardiovascular risk profile of participants who underwent CMR was similar to that of those who were screened (Table 1) . At the time of CMR, Ϸ50% of participants had hypertension with the majority (41% of participants) using antihypertensive medications; 11.5% of the participants reported current smoking. Sixty-four percent of the cohort had hypercholesterolemia, with 57% of the cohort treated with lipid-lowering medications.
Compared with the full CMR cohort, participants who had delayed-enhancement CMR had a slightly lower prevalence of hypertension and use of antihypertensive medications, minimally lower mean HbA 1c levels (Ϸ0.1% lower), lower total cholesterol (2 mg/dL less), and lower triglyceride levels (Ϸ3 mg/dL less; Table 1 ). The Framingham Risk Score 24 was the same for the entire screened cohort, the CMR cohort, and the gadolinium CMR cohort. Table 1 also presents the prevalence of diabetic complications at the time of the CMR examination. In participants undergoing CMR, the prevalence of clinical or silent MI was 3.6%, retinopathy was 20.3%, macroalbuminuria or end-stage renal disease was 9.6%, autonomic neuropathy was 31.7%, and peripheral neuropathy was 29.4%. Except for retinopathy, these complication rates were slightly lower than in the participants who screened for CMR.
The CVD characteristics of participants with delayedenhancement CMR were similar to those of the screened study cohort ( Table 1 ). The prevalences of clinical or silent MI, nonzero coronary artery calcium score, and common carotid artery intima-media thickness were not significantly different among the screened cohort, CMR, and gadolinium CMR participants. However, retinopathy, macroalbuminuria/end-stage renal disease, and autonomic and peripheral neuropathy were less frequent in participants with delayed-enhancement CMR than those without (PϽ0.0001 for all except autonomic neuropathy, Pϭ0.002 for autonomic neuropathy). Table 2 shows measures of cardiovascular function by sex. Except for ejection fraction, ankle-to-arm ratio, and cardiac index, all parameters were higher among men than women. The prevalence of an ankle-to-arm ratio Ͻ0.9 and ejection fraction were higher in women than in men. Cardiac index was not significantly different between the sexes. Cardiovascular function measures for participants with delayedenhancement imaging were similar to those of the total cohort with CMR. Table 3 presents the multivariate model for LV parameters in relationship to CVD risk factors. LV mass and end-diastolic volume (EDV) were 3.1 g and 4 mL less per each 10-year increase in age and 4 g and 5.1 mL less in the secondary intervention cohort compared with the primary prevention cohort, respectively. LV mass was positively associated with smoking, macroalbuminuria, and mean SBP (7.6 g, 8.3 g, and 14.8 g/10 mm Hg, respectively). No significant association was noted between LV mass and mean HbA 1c . LV EDV was positively associated with alcohol use (5.6 mL) and inversely associated with mean HbA 1c level (Ϫ2.9 mL/1%). CVD risk factors accounted for 58% of variability of LV mass and 46% variability of EDV after adjustment for height, weight, and machine type. Stroke volume was 2.2 mL less per each 1% increase in mean HbA 1c level, 2.1 mL greater per each 10-mm Hg increase in SBP, and 3.3 mL greater in participants with versus without alcohol use. Neither mean HbA 1c nor macroalbuminuria was related to stroke volume. Ejection fraction was not associated with any traditional risk factors, mean HbA 1c , or macroalbuminuria. Cardiac output was directly related to SBP (0.3 L/min per 10 mm Hg) and alcohol use (0.2 L/min) and inversely related to age (Ϫ0.3 L/min per 10 years).
LV Structure and Function in Relation to CVD Risk Factors
Greater ratio of LV mass to EDV indicates concentric remodeling. The ratio of LV mass and EDV is normally close to unity for both men and women. The ratio of LV mass to EDV showed a positive relationship to SBP (0.05 g/mL per 10 mm Hg), mean HbA 1c (0.03 mL/1%), and macroalbuminuria (0.08 g/mL with positive history of macroalbuminuria).
Table 2. Imaging Measures of Epidemiology of Diabetes Interventions and Complications Participants Among Men and Women in the Full Cardiac Magnetic Resonance Cohort and Among Those With Gadolinium-Delayed Enhancement
There was no relationship of study cohort to cardiac output and ratio of LV mass to EDV.
Owing to the correlation between height and weight, additional analyses like those in Table 3 were conducted without adjustment for height and weight or for appropriate measures using values indexed to (divided by) body surface area (see the Results section and Table IIA and IIB in the online-only Data Supplement). The direction and magnitude of significant associations in Table 3 were similar after these analyses.
Additional models were also explored in which a value of 10 mm Hg was added to all SBP values obtained while a subject was taking antihypertensive medications before calculating the weighted mean for each subject. Stroke volume was no longer significant with this approach (estimate, 1.9 mL [SE, 0.6 mL] per 10 mm Hg increment in SBP compared with values of 2.1 mL [SE, 0.6 mL] per 10 mm Hg increment in SBP shown in Table 3 ). LV mass, cardiac output, and LV mass/EDV showed no substantial effect of this SBP adjustment.
Prevalence of Myocardial Scar
The overall prevalence of myocardial scar was 4.3% (32 of 741). Sixteen patients had ischemic scar (Figure 2A ) and 16 had nonischemic scar ( Figure 2B ). Men had a higher prevalence of scar compared with women (5.8% versus 2.2%, respectively; PϽ0.05). The average mass of ischemic scar was 11Ϯ10.2 g, whereas that of nonischemic scar was 3.3Ϯ4.5 g (PϽ0.05).
Among the 32 participants with myocardial scar by CMR imaging, only 6 (19%) had previously experienced a clinically adjudicated MI; all 6 of these participants had an ischemic myocardial scar by CMR ( Table 4 ). Five of 32 participants (16%) had evidence of silent MI. Among these 5 participants, 3 had ischemic and 2 had nonischemic myocardial scarring. Of those without a myocardial scar by CMR (nϭ709), 4 (0.6%) had an adjudicated clinical MI and 13 (1.8%) had an ECG-defined silent MI (Table 4 ). Of EDIC participants with no evidence of adjudicated MI or ECGdefined MI (nϭ713), 21 (2.9%) had CMR-defined scars, most of which were an nonischemic rather than ischemic pattern (14 of 21, 66.7%; Table 4 ). Table 5 presents separate, minimally adjusted logistic regression models to assess the influence of individual factors on *In addition to the above factors, the full model includes the machine type (Siemens versus Philips versus GE), height, and weight. †The proportion of variability explained (R 2 ) by the CV risk factors alone was obtained from a model that included smoking, drinking, height, weight, mean SBP, HDL, LDL, and HbA 1c , and history of macroalbuminuria (AER Ն300 mg/24 h ever, yes versus no). ‡Cohort (2 versus 1): secondary intervention cohort (2) that had diabetes for 1 to 15 years with mild to moderate nonproliferative retinopathy and urinary AER Ͻ200 mg/dL at the Diabetes Control and Complications Trial baseline versus primary prevention cohort (1) that had diabetes for 1 to 5 years with no related complications.
Myocardial Scar in Relation to CVD Risk Factors
§PՅ0.01 for both before and after Hochberg corrections. PՅ0.01 before Hochberg corrections and 0.01ϽPՅ0.05 after Hochberg corrections.
the risk of myocardial scar. With only 32 subjects with observed scars, the data were insufficient to permit a more robust multivariate analysis. Male patients had 2.5 (95% CI, 1.1-5.9) times higher odds (risk) of having myocardial scar compared with female patients (Pϭ0.034; Table 5 ). Each 10-year increase in age was associated with a 2.2-fold (95% CI, 1.2-4.0) higher risk of myocardial scar (Pϭ0.008). Hypertensive participants (including those on antihypertensive medications) had 2.4fold (95% CI, 1.1-5.2) higher odds of having myocardial scar than normotensive participants. Participants who had higher mean high-density lipoprotein cholesterol had a lower risk of having myocardial scar (odds ratio, 0.96 [95% CI, 0.93-1.00] per 1-mg/dL higher mean high-density lipoprotein cholesterol; Pϭ0.043). Participants with higher mean HbA 1c had 1.5-fold greater odds of having myocardial scar per 1% increase (Pϭ0.049). Additionally, participants with macroalbuminuria also had 4.0-fold (95% CI, 1.4 -11.6) higher odds of having myocardial scar compared with those without macroalbuminuria (Pϭ0.011; Table 5 ).
Greater LV mass, end-systolic volume, and EDV indexes were significantly associated with higher odds for myocardial scar (adjusted odds ratios, 1.04 [95% CI, 1.0 -1.1] per 1-g/m 2 increase in LV mass index, Pϭ0.022; 1.03 [95% CI, 1.0 -1.1] per 1-mL/m 2 increase in EDV index, Pϭ0.016; 1.10 [95% CI, 1.05-1.14] per 1-mL/m 2 increase in end-systolic volume index, PϽ0.0001; Table 5 ). The odds of myocardial scar was greater in association with lower ejection fraction (adjusted odds ratio, 0.86; [95% CI, 0.8 -0.9] per 1% increase in ejection fraction; PϽ0.0001; Table 5 ).
Discussion
The DCCT/EDIC is the first large-scale cohort of patients with type 1 diabetes mellitus evaluated by CMR. The main conclusions are the following: (1) Mean SBP, smoking, and macroalbuminuria were associated with greater LV mass, with the magnitude of the associations greatest for patients with macroalbuminuria; (2) higher mean HbA 1c (over Ϸ22 years of follow-up) was associated with smaller LV volumes but similar LV mass when adjusted for other risk factors; (3) ratio of LV mass to volume, an indicator of concentric LV remodeling, was positively associated with mean SBP, macroalbuminuria, and mean HbA 1c ; and (4) the prevalence of myocardial scar by CMR was 4.3% compared with only 1.4% of patients with clinically recognized MI. Older age, male sex, hypertension, macroalbuminuria, elevated mean HbA 1c , reduced high-density lipoprotein levels, greater LV mass and volume index, and reduced global LV function were associated with higher risk of myocardial scar.
The term diabetic cardiomyopathy refers to diabetic patients with LV dysfunction with signs and symptoms of heart failure. Stage 1 diabetic cardiomyopathy, the earliest form, has been characterized by diastolic dysfunction with normal global ejection fraction. 25 Adverse myocardial remodeling, defined by a greater ratio of LV mass to EDV, and LV hypertrophy contribute to diastolic dysfunction and are independent predictors of cardiovascular events in the general population. 26, 27 Greater LV mass was observed in type 1 diabetes mellitus when the disease was complicated with nephropathy 28 or autonomic neuropathy 29 but not in uncomplicated diabetes mellitus. 30 Whether LV hypertrophy is independent of modifiable risk factor in type 2 diabetes mellitus is controversial. 31, 32 Our findings extend previous studies by showing macroalbuminuria as the strongest determinant of LV mass among the markers assessed in type 1 diabetes mellitus, even compared with traditional "modifiable" risk factors. Increased myocardial mass in the presence of diabetic nephropathy is likely a multifactorial process, with nonhemodynamic factors such as activation of the renin-angiotensin system exerting a pathogenetic role. 33 Greater LV mass was also 
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associated with smoking and SBP in our DCCT/EDIC cohort in a manner similar to that in "healthy" individuals. 34 The common risk factors in various normal and patient populations corroborate the importance of risk factor reduction in type 1 diabetes mellitus to improve cardiovascular outcome. Long-term glycemic control, measured by mean HbA 1c levels, failed to show an independent association with LV mass (ie, cardiac hypertrophy). However, a greater ratio of LV mass to EDV, indicating adverse concentric remodeling, was positively associated with HbA 1c levels and macroalbuminuria. In the Multiethnic Study of Atherosclerosis (MESA) study, white participants with type 2 diabetes mellitus had lower EDV and stroke volume compared with white partici-pants with normal fasting glucose after adjustment for confounders. 31 CMR-identified myocardial scar, an important predictor of adverse cardiovascular outcomes, was present in 28% of symptomatic type 2 diabetics (107 patients; mean age, 63 years), 35 24% of elderly subjects at 70 years of age (248 subjects), 36 and 9.4% of patients with manifest arterial disease or marked risk factors for atherosclerosis (480 patients; mean age, 53 years). 37 The DCCT/ EDIC cohort has a low rate of myocardial scar (4.3%), albeit in younger patients who were mostly asymptomatic. Reduced global LV function and greater LV mass were associated with the presence of myocardial scar in prior reports, [35] [36] [37] similar to our results in the DCCT/ EDIC cohort. These results suggest that determinants of myocardial scar may be similar across a wide range of subjects who have a high risk profile for CVD. Additionally, DCCT/EDIC participants with hypertension, macroalbuminuria, and higher mean HbA 1c and those using lipid-lowering medications had higher odds of having myocardial scar.
The concordance between history of MI and the presence of myocardial scar was relatively low. Approximately 65% of participants who had myocardial scar by CMR had no clinical evidence of prior MI. Similar to our findings, Kwong et al 38 (195 patients) and Kim et al 39 (85 patients) reported that most patients with myocardial scar by CMR did not have significant Q-wave changes. "Pathological" Q waves are not 100% specific and may underestimate or overestimate the true prevalence of silent MI. 36 Conversely, in our cohort, CMRdefined myocardial scar was not present in 4 patients with adjudicated MI. Reasons for this discrepancy could include very small scar size, successful revascularization of coronary stenosis before scar tissue develops, incorrect adjudication, or interval resolution of myocardial scar.
There are several limitations of the present study. Of the 1240 subjects who were screened in EDIC, Ϸ18% (nϭ223) did not complete the CMR examination. Of 1017 participants with CMR, 262 (26%) were excluded from gadolinium administration mainly as a result of moderate or worse renal dysfunction, renal transplantation, or dialysis. The risk for myocardial scar in the excluded participants may be higher than in those patients who were included. Coronary angiograms were not available; thus, we do not know whether CMR scar in our cohort is due to microvascular complications of diabetes mellitus or to occlusive coronary artery disease. In addition, nonischemic CMR scar can be seen in a wide range of nondiabetic, nonischemic cardiomyopathies such as myocarditis and hypertrophic and dilated cardiomyopathy.
The DCCT/ EDIC cohort may not be representative of patients with type 1 diabetes mellitus in the community owing to long-term cohort evaluation. There was no significant difference in incidence of clinical or silent MI between 741 participants and 276 nonparticipants in the gadolinium CMR. However, patients with a potentially healthier cardiovascular profile underwent CMR. Interestingly, despite the exclusion of patients with moderate or severe renal insufficiency, the presence of macroalbuminuria was associated with a 3.5-fold higher likelihood of myocardial scar. DBP indicates diastolic blood pressure; SBP, systolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA 1c , hemoglobin A 1c ; ESRD, end-stage renal disease; and LV, left ventricular. *The model for each covariate is also adjusted for sex and age. Sex was adjusted for age alone; age and diabetes duration were adjusted for sex alone. The odds ratio is as presented for 1 category versus another for a categorical covariate or per unit increase for quantitative covariates.
†Covariate at time of CMR.
